New analysis identifies patient populations with cancer-associated VTE who could benefit from treatment with oral, once-daily LIXIANA (edoxaban)

New analysis identifies patient populations with cancer-associated VTE who could benefit from treatment with oral, once-daily LIXIANA (edoxaban)

Emmanuele Kouvousis MD,MSc Emmanuele Kouvousis MD,MSc

Emmanuele Kouvousis MD,MSc

Non Invasive Cardiologist (ECFMG certified)

发布日期: 2018年8月7日
+ 关注
  • Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE
  • This analysis provides benefit/risk assessment in different types of cancer patient populations1
  • In those with non-gastrointestinal cancer, the risk of major bleeding was comparable1

Benefit/Risk assessment in different types of cancer patient populations

要查看或添加评论，请登录

Emmanuele Kouvousis MD,MSc的更多文章

社区洞察

其他会员也浏览了